Patient P-01644
Synthetic patientNBL-101 · Day 96 · 55–64 · M · baseline S03Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Improving
Nutritional resilience
Favorable
Discontinuation risk
13%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S03
- Day 10 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 10.
Primary contributors, last 14 days
- Inflammatory activity-9
- GI instability-6
- Toxicity-2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion11.2/100
improving · -4.8 vs previous 14 d
Toxicity
Blood25.9/100
worsening · +13.3 vs previous 14 d
Sleep quality
Wearable70.2/100
improving · +4.4 vs previous 14 d
Energy level
Daily log5.7/10
worsening · -0.3 vs previous 14 d
Stress level
Daily log3.7/10
worsening · +0.4 vs previous 14 d
Steps
Wearable5,901
worsening · -440 vs previous 14 d
Adherence
Companion89.3 %
stable · -3.5 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 78 from the failing basin, 29 from restoration.
Good elements to keep
- Daily walks resumedperturbation · steering +3.3
Main detractors to watch
- Low butyrate capacityhidden · steering -17.5
- Spicy / capsaicinperturbation · steering -8.3
- Simple carbohydratesperturbation · steering -7.9
- Low microbial diversityhidden · steering -7.7
- Spicy / capsaicindetractor · GI +4.8 next day
- Simple carbohydratesdetractor · GI +4.5 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Spicy / capsaicin+4.8detractor · 95%
- Simple carbohydrates+4.5detractor · 95%
- Dietary fat load+3.7detractor · 94%
- Insoluble fibre-2.3no signal · 53%
- Alcohol+0.6no signal · 15%
- Histamine load-0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 26/100
- Inflammatory signalling ↓25
- DNAIL6 -174 variant raises baseline inflammatory tone
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Normal metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 2.2 · butyrate capacity 26/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 60 ms
- Sleep
- 7.7 h
- Steps
- 6,141
- Resting HR
- 61 bpm
Daily log: GI score 11, nutritional resilience 62, adherence 89.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01861 | 47% | S12 | HY-01 | improved | 47 |
| P-01346 | 42% | S12 | DT-01 | improved | 52 |
| P-01374 | 42% | S08 | HY-01 | improved | 49 |
| P-01455 | 42% | S01 | GI-04 | improved | 61 |
| P-01555 | 42% | S06 | GI-04 | improved | 56 |
| P-01618 | 42% | S10 | GI-04 | improved | 39 |
| P-01752 | 42% | S20 | DT-01 | improved | 50 |
| P-01342 | 41% | S11 | DT-01 | improved | 48 |
| P-01320 | 40% | S09 | HY-01 | improved | 38 |
| P-01724 | 39% | S10 | DT-01 | improved | 63 |
| P-01385 | 38% | S06 | HY-01 | improved | 50 |
| P-01593 | 38% | S10 | HY-01 | improved | 56 |